Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Design Therapeutics ( (DSGN) ) has issued an announcement.
On April 28, 2026, Design Therapeutics reported first-quarter 2026 financial results and operational progress across its GeneTAC pipeline, while also posting an updated investor presentation with a recorded narrative on its website. The company ended the quarter with $222.8 million in cash, cash equivalents and investment securities, reported a net loss of $17.6 million on R&D expenses of $14.4 million and G&A expenses of $5.3 million, and said this capital is expected to fund planned operations into 2029.
During the quarter, Design continued dosing Friedreich ataxia patients in its RESTORE-FA Phase 1/2 multiple ascending dose trial of DT-216P2, which evaluates safety, pharmacokinetics and frataxin biomarker responses over four- or 12-week treatment periods, with an update on endogenous frataxin levels expected in the second half of 2026. The pipeline advanced with an ongoing Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy, planned initiation of a Phase 1 MAD trial of DT-818 in myotonic dystrophy type-1 in the first half of 2026, continued preclinical work in Huntington’s disease, and the March 2026 appointment of veteran drug developer David Shapiro, M.D., to the board of directors, bolstering clinical and regulatory expertise.
The most recent analyst rating on (DSGN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, sizable and rising losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technically, the stock is in an uptrend, but overbought readings temper the momentum signal. Valuation is also limited by lack of profitability and no dividend support.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Design Therapeutics, Inc. is a clinical-stage biotechnology company developing GeneTAC gene targeted chimera small molecules aimed at modulating expression of disease-causing genes in serious degenerative genetic diseases. Its lead programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and a preclinical program in Huntington’s disease, with additional genomic medicine discovery efforts underway.
Average Trading Volume: 281,679
Technical Sentiment Signal: Buy
Current Market Cap: $772.8M
See more data about DSGN stock on TipRanks’ Stock Analysis page.